Skip to content
DeepViews

Amphastar Pharmaceuticals, Inc. (AMPH) — 分析摘要

Amphastar Pharmaceuticals, Inc.(AMPH)的市值为1.02十亿美元,最近一年的营收同比增长了-1.7%。净利润率为13.6%。当前市盈率为12.9倍。

核心要点

  • 营收同比变化-1.7%
  • 净利润率13.6%
  • 市盈率12.9倍

与PHARMACEUTICAL PREPARATIONS板块的其他公司相比,AMPH的营收增长为-1.7%,市盈率为12.9倍。

[XNAS]

Amphastar Pharmaceuticals, Inc. (AMPH)

$23.91

更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$1017.08M
企业价值
$1336.52M
市盈率
12.9
股息率
0.00%
EV/EBITDA
9.1
公司简介
关于
关于 Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

行业

PHARMACEUTICAL PREPARATIONS

员工人数

1,976

总部

RANCHO CUCAMONGA, CA

Exchange

XNAS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒
55
窄护城河

基于 4 年财务数据的系统性竞争优势评估

此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$768.16M
总债务$609.56M
债务权益比0.79
现金及等价物$223.61M

现金流

经营现金流$184.61M
自由现金流$152.89M
自由现金流率20.94%
P/FCF 比率6.65
Source: Polygon.io · SEC EDGAR
股息
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。